



 **ALZHEIMER'S[®]
ASSOCIATION**

2024

ANNUAL REPORT

FISCAL YEAR 2024 (JULY 1, 2023 – JUNE 30, 2024)



Alzheimer's Association

225 N. Michigan Ave., Fl. 17

Chicago, IL 60601

alz.org

800.272.3900

The Alzheimer's Association is the leading voluntary health organization in Alzheimer's disease care, support and research. We provide services to those affected by Alzheimer's, advocate for policy change and scientific funding, and advance research toward prevention, treatment and, ultimately, a cure.

A donor-supported organization, the Association allocates its funds in an ethical and responsible manner that exceeds the rigorous standards of America's most experienced charity evaluator, the Better Business Bureau Wise Giving Alliance. The Association also holds a National Charity Seal from the Alliance.

We are especially grateful to those who helped us advance our mission in fiscal year 2024 by making contributions. Total revenues equaled more than \$465 million.

Our mission


The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support.

Our vision

is a world without Alzheimer's and all other dementia.

Join our cause

[Learn how you can get involved.](#)



A Letter from Our Leaders

As we reflect on all the ways the Alzheimer's Association moved our mission forward this year, it is clear that we are having an undeniable impact on people living with dementia, care partners and families. Guided by our volunteer leaders in communities across the country, we are accelerating research, advancing public policy, supporting people when and where they need it, bringing more people to our work — and continuing to build a groundswell of momentum for our cause. That momentum propelled the Association to a record year of fundraising, which will bolster our continued investments in groundbreaking research, support for people living with dementia, and risk reduction and early detection efforts.

The new era of treatment and care is bringing so many people hope. For some, especially those facing a diagnosis, treatments mean hope for more time. For others, this moment represents hope for the future — that additional treatments, diagnostic tools, prevention strategies and life-changing breakthroughs for all communities are within reach.

Here are just a few highlights from 2024:

- » **Increasing access to treatment.** Thanks to the foundation laid by our powerful grassroots advocates and public policy team in the previous year, the Centers for Medicare & Medicaid Services (CMS) announced Food and Drug Administration (FDA)-approved treatments would be covered under Medicare and Medicaid. After the CMS announcement, most major private payers followed suit.
- » **Advancing research.** We invested more than \$109 million across our research platform — a single-year record. We currently have more than \$430 million invested across over 1,110 projects in 56 countries. This level of funding is both an investment in the careers of the visionaries and innovators who may discover the next big breakthrough and an investment in our future momentum as discoveries come to light in the years ahead.
- » **Supporting people living with dementia and care partners.** We reached more than 567,000 people with information, education and support through our free 24/7 Helpline, alz.org, awareness presentations and more. We also influenced the care of 16 million people through our work with health systems, health care payers and long-term care providers.
- » **Engaging communities.** People in communities across the country are stepping up to engage in our fundraising efforts, including in Walk to End Alzheimer's®, our signature event, which raised a record \$100 million for our cause. And across all areas of our mission work, we are engaging our constituents in meaningful and impactful ways. We partnered with more than 1,400 local and national organizations reaching diverse audiences last year. In addition, more than 11,000 researchers and scientists attended our global Alzheimer's Association International Conference® 2023 (AAIC®) in person or virtually.

Together, we have much progress to celebrate — and much work left to do. For the millions of people affected by Alzheimer's today and everyone who will be touched by the disease tomorrow, we will continue our relentless work to ensure everyone in all communities has access to prevention, early detection, treatment, care and, ultimately, cures.

Thank you for your steadfast support, and for all that you do to advance our vision of a world without Alzheimer's and all other dementia.

Warmly,



Joanne Pike
Joanne Pike, DrPH
President and CEO



Sarah J. Lorance
Sarah Lorance
FY23 Board Chair



Report Overview

The FY24 Annual Report details mission-related accomplishments within the six strategic objectives of the Alzheimer's Association: providing and enhancing quality care and support; accelerating research; increasing concern and awareness; strengthening diversity, equity and inclusion; advancing public policy; and increasing revenue. These initiatives drive the Association's efforts to end Alzheimer's and all other dementia and offer help and hope to all those affected.

Providing and Enhancing Quality Care and Support

Available via locations in communities nationwide, our award-winning website, alz.org, and our 24/7 Helpline (800.272.3900), the Association is instrumental in providing and enhancing care and support for all those affected by Alzheimer's and all other dementia through a commitment to reliable resources, support and information. We work directly with impacted families, and we collaborate with health systems, long-term care and community-based services nationwide to facilitate solutions for delivering person-centered dementia care.

Accelerating Research

The Association is the world's largest nonprofit funder of Alzheimer's and dementia research. In our role as the leading research convener, collaborator and coordinator, the Association is committed to accelerating global progress toward new methods of diagnosis, treatment, prevention and, ultimately, a cure.

Increasing Concern and Awareness

The Association drives the nationwide discussion of Alzheimer's and all other dementia and is the leader in the fight to end its devastation. By growing the conversation about the number of individuals affected by Alzheimer's and its staggering economic and societal impact, the public and policymakers are enabled to take appropriate actions to change the course of the disease, and families can be empowered to raise their voices as they face its challenges.

Strengthening Diversity, Equity and Inclusion

The Association has long highlighted diversity, equity and inclusion as part of core values critically important to our work. We are committed to identifying and addressing barriers that may impede members of diverse communities from receiving Alzheimer's education, care and support and to improving interventions and treatment for everyone.

Advancing Public Policy

As the leading voices for Alzheimer's advocacy, the Association and the Alzheimer's Impact Movement (AIM), a separately incorporated advocacy affiliate, successfully fight for critical research and care and support initiatives at the state and federal levels. (AIM also engages in certain political activities that the Association is prohibited from conducting; those activities are not included in this report.) Together with our hundreds of thousands of advocates, we are relentless in our efforts to make Alzheimer's a national priority while speaking up for the needs and rights of people living with the disease.

Increasing Revenue

Individuals, corporations and foundations further the Association's mission through their dedicated involvement and support. From Walk to End Alzheimer's to fundraising galas to estate gifts and more, the Association deeply appreciates our many generous donors who demonstrate their powerful, ongoing commitment to ending Alzheimer's through advancing research and enhancing the Association's care and support efforts.

Providing and Enhancing Care and Support

Delivering on its mission, the Alzheimer's Association provided care and support more than 10 million times in FY24 through channels including [alz.org](https://www.alz.org), care consultations, information and referrals, support groups, education programs and information. In this new era of treatment, the Association remains committed to ensuring people in every stage of the disease have access to programs and services to diagnose and treat dementia, as well as support through their journey. Surveys indicate that constituents are highly satisfied with Association programs and services and would recommend them to others.

Nearly 4,500 trained Alzheimer's Association **community volunteers provided our awareness, education and support programs**. These volunteers were supported by outreach volunteers who ensure that communities have education, information and support where they live, work and play. Our volunteers donated nearly 180,000 hours of service valued at more than \$5.7 million contributed dollars and provided more than 423,000 interactions with people living with Alzheimer's and their families.

The Association's free **24/7 Helpline** (800.272.3900) is available around the clock, 365 days a year. Specialists and master's-level clinicians received over 223,000 calls, emails and online chats, offering confidential support and information to people living with dementia, caregivers, families and the public. The service is partially funded by a five-year, \$10 million federal grant awarded by the Department of Health and Human Services Administration for Community Living.

Through a five-year, \$25 million grant — the largest in Association history — from the Administration on Community Living (ACL), part of the Department of Health and Human Services, the **Center for Dementia Respite Innovation** fosters innovation in respite care models and enhances respite services for people living with dementia and their caregivers, particularly in underserved communities. The center works to address the disparity and burden of care faced by many families of those living with Alzheimer's and other dementia and is a key element of our effort to reduce disparities.

The Association worked with **400 health systems** to increase equitable access to care and improve the quality of care through changes in systems, policy and practice. The Association's health systems initiatives benefited more than 16.48 million covered lives — a 23% increase over FY23. Of these covered lives, an estimated 4.5 million benefited

from our efforts to engage over 50 payers for access to new treatments.



The Association **expanded its Project ECHO® program** to increase influence and equitable access to diagnosis, care and support. The Association became the first ECHO Superhub for dementia, equipped to train new and existing ECHO hubs to establish their own dementia-focused programs. In addition, the Dementia Care Global ECHO Collaborative grew to 31 partners across three continents. The Association's Alzheimer's and Dementia Care ECHO Program trained medical professionals and professional care providers in a telementoring format, resulting in over 500,000 influenced lives. In addition, the Project ECHO for Public Health Professionals was held for the first time, in collaboration with the Public Health Center of Excellence on Dementia Risk Reduction, to increase knowledge on dementia risk factors and integrate messaging into chronic disease prevention efforts.

In partnership with the Association, the Joint Commission launched **Memory Care Certification for Assisted Living Communities (ALCs)**. The voluntary, specialty certification

recognizes Joint Commission-accredited ALCs that meet its standards to support the delivery of high-quality care for residents diagnosed with Alzheimer's or another dementia. The new certification requirements reflect current evidence-based practices in memory care, align with the Association's Dementia Care Practice Recommendations and build on existing requirements for the Joint Commission's Assisted Living Community Accreditation Program.

The Association was successful in its applications to two states — Indiana and Montana — and was awarded over \$380,000 in **Civil Monetary Penalty (CMP)** dollars. The CMP Reinvestment Program uses federal government fines collected from nursing homes to fund projects that improve resident quality of life in skilled nursing facilities in every state. These funds will support over 70 nursing homes and 1,500 professional care staff over the next two to three years with a comprehensive model of training, certification and family support.

The Association launched the **Dementia Care Navigation Roundtable** with nearly 30 member organizations, including health care providers, payers, researchers and other stakeholders who are committed to advancing the delivery of high-quality, person-centered dementia care navigation. The roundtable promotes shared definitions, standards and best practices; identifies challenges and opportunities for ongoing research and innovation; and ensures all voices are heard and represented in developing guidelines for care navigation.

The Association partnered with Rippl, a health technology company with expertise in on-demand dementia support, to create the **Dementia Care Navigation Service**. The service was chosen by the Centers for Medicare & Medicaid Services (CMS) through a competitive application process to participate in an eight-year pilot program, **Guiding an Improved Dementia Experience (GUIDE) Model**, led by the CMS Center for Medicare and Medicaid Innovation. The Dementia Care Navigation Service helps people living with dementia and their caregivers access clinical and care management, caregiver education and support, and respite services.

Nearly 3,000 professional care providers working in long-term and community-based care settings completed the online **essentiALZ® – Alzheimer's Association Training and Certification** program, now also available in Spanish. Learners who complete the essentiALZ training and certification can claim credit for continuing nursing education (CNE), National Association of Long-Term Care

Administrator Boards (NAB), and continuing education for social work, physical therapy, psychology, occupational therapy and nutrition to continue to improve the quality of care for those living with Alzheimer's and other dementia.

The Association launched an in-person English version of its evidence-based education program **The Empowered Caregiver**. The program teaches caregivers how to navigate the responsibilities of caring for someone living with dementia and features five topics, including building foundations of caregiving, supporting independence, communicating effectively, responding to dementia-related behaviors, and exploring care and support services.

The Association's interactive online tool, **ALZNavigator™**, creates customized action plans for all individuals impacted by the disease and offers specific resources for LGBTQ+ individuals, veterans, people living with younger-onset Alzheimer's and people who do not yet have a diagnosis. FY24 saw over 38,000 sessions conducted by nearly 31,000 users, almost all of whom were new to the platform.

ALZConnected®, the Association's free online community, provides a space where people living with dementia and their caregivers can post questions about dementia-related issues, offer support, and create public and private groups around specific topics. The community welcomed over nearly 14,000 new users, a more than 10% growth in membership.

Constituents engaged in more than 500,000 sessions using the **Alzheimer's Association & AARP Community Resource Finder**, a growing database of dementia and aging-related resources. Community Resource Finder connects individuals living with dementia and their caregivers with local programs and services.



Over 25,000 people have registered for [ALZ Talks](#), the Association's free webinar series featuring friendly and insightful conversations on a variety of topics with people living with Alzheimer's, caregivers and dementia experts. To date, ALZ Talks has received nearly 65,000 on-demand views through YouTube and over 9 million views on Facebook.



The [Alzheimer's Association National Early-Stage Advisory Group](#) comprises individuals living in the early stage of Alzheimer's or another dementia who share their experiences through media outlets and other public channels to raise awareness, reduce stigma and provide guidance on the development of Association programs and services. Among other activities, members from across the country spoke about their lived experience and ensured the voice of people living with the disease remains at the center of our work. Advisors advocated for approval of and access to treatments that can slow disease progression, including speaking to the FDA Peripheral and Central Nervous System Drugs Advisory Committee to encourage the committee to consider the personal experience and impact of the disease on those living with it and their families as part of their decision-making process.

The Association addresses Alzheimer's as a public health issue by promoting brain health, increasing access to early detection and diagnosis, and supporting people living with dementia and their caregivers. [The 10 Healthy Habits for Your Brain](#) campaign launched in English and Spanish, encouraging audiences of all ages to take charge of their brain health.

The third cohort of **Healthy Brain Initiative Road Map Strategists** was selected to build capacity within its 10 local health departments and tribal health organizations to address brain health in their communities. The Alzheimer's Association **Public Health Center of Excellence on Dementia Risk Reduction** completed the pilot of its Community Convenings project with local health departments and launched the new Risk Reduction Learning Collaborative to increase the knowledge and confidence around dementia risk reduction among public health officials working in communities.

Over 200 community members and experts were engaged to shape the new **Healthy Brain Initiative: Road Map for American Indian and Alaska Native Peoples**. The publication will help professionals conducting public health work with tribes, nations, pueblos, bands, villages and urban Indian organizations select and pursue strategies for the American Indian and Alaska Native communities they serve to improve brain health, improve detection, address dementia and better meet the needs of caregivers.

Accelerating Research

The Association committed a record \$109 million in total annual research spending, the largest allocation since the organization's founding, including more than \$76 million in grants for new scientific investigations. These grants represent proposals ranked highest by a three-tier peer-review process in a highly competitive field. As the world's leading nonprofit funder of Alzheimer's and dementia research, the Association is currently investing more than \$430 million in over 1,110 active projects in 56 countries, spanning six continents.

The Association continues to drive the diversification of clinical trials through the [Part the Cloud](#) global research grant program. In FY24, Part the Cloud provided over \$2.9 million to move forward three new high-risk, high-reward studies aimed at potential treatments. The continued success of Part the Cloud is due to the drive and vision of philanthropist and longtime Alzheimer's Association champion Mikey Hoag; since Hoag founded Part the Cloud in 2012, the program has funded 71 studies that have generated more than \$1.4 billion in follow-on funding.

The [U.S. POINTER](#) study continues to work to better understand the relationship between lifestyle interventions and dementia risk. With recruitment complete, more than 2,000 people are enrolled via study sites in Chicago (Advocate Health Care, Rush University Medical Center), Houston (Baylor College of Medicine in collaboration with Kelsey Seybold Foundation), Providence, Rhode Island (Butler Hospital in collaboration with LifeSpan), Sacramento, California (UC Davis School of Medicine), and Winston-Salem, North Carolina (Wake Forest School of Medicine), and over 30% of participants are from historically underrepresented populations. The Association has invested over \$60 million in U.S. POINTER, and the National Institute on Aging (NIA) has made four awards expected to total up to nearly \$65 million for add-on studies. In FY24, the Association committed additional funding to engage and monitor participants for four years following their exit from the study. U.S. POINTER results are expected to be reported at the Alzheimer's Association International Conference® 2025 (AAIC®).

The Association supported recruitment and retention activities for the [Longitudinal Early-Onset Alzheimer's Disease Study \(LEADS\)](#), a two-year observational study designed to understand the genetic, biological and clinical processes involved in younger-onset (or early-onset) Alzheimer's disease — defined as when symptoms develop before age 65. LEADS recently achieved full enrollment for the study of 600 individuals and has reopened recruitment

of cognitively impaired individuals to expand the number of participants to 850 across 18 sites in the United States.

The Association has been a funder of the [Alzheimer's Disease Neuroimaging Initiative \(ADNI\)](#) since its advent in 2004. The current iteration of the study, ADNI4, is a five-year extension of the original study, fully funded by the NIA. Since its inception, the goal of ADNI has been to validate biomarkers for Alzheimer's disease clinical trials, and ADNI in its several incarnations has had a major impact on Alzheimer's research and clinical trials, yielding more than 6,200 scientific publications.

The Alzheimer's Association, Global Brain Health Institute (GBHI) and the UK-based Alzheimer's Society announced 26 awardees in 16 countries of the [Pilot Awards for Global Brain Health Leaders](#), a competitive funding initiative dedicated to bridging the gaps in dementia diagnosis, treatment and care among underserved populations worldwide. These awardees will join 137 previously funded pilots in 42 countries, bringing the total to \$4.1 million in 45 countries. Since the program launched, awardees have leveraged their projects for an additional \$16.1 million investment directly related to their pilot projects. The visionary work of the awardees has led to a total of more than \$93.5 million to further advancements of dementia-related resources.

A foundation that chooses to remain anonymous continues to partner with the Association on a collaboration that links funding team science through ongoing consortia and open call requests for applications in different emerging science areas. In FY24, the partnership, called the **AD Strategic Fund**, awarded over \$7 million to team science collaborative projects. The partnership will continue its work in FY25 with additional funding in focused programs and open collaborative projects. In addition, the AD Strategic Fund funded five continuation awards to better dissect and understand the biological underpinnings of APOE in Alzheimer's.

The Association furthers therapeutic development through the **Tau Pipeline Enabling Program** partnership with the Rainwater Charitable Foundation. In FY24, the Association and the foundation funded five new studies, totaling nearly \$4 million, bringing the total investment in tau-related drug discovery and drug development projects by the two partners to \$14.6 million. All new studies are directed toward a unique aspect of tau biology and utilize a diverse array of therapies.

In a new funding program with the American Society of Neuroradiology, we launched a **pilot funding program with three new joint awards**. The partnership, which was recognized at the society's annual meeting, will continue in FY25.

The Association continued to provide leadership and support for **New IDEAS: Imaging Dementia — Evidence for Amyloid Scanning Study**, alongside the American College of Radiology (ACR), the Centers for Medicare and Medicaid (CMS) and recruitment experts from Vanderbilt University and the University of North Carolina at Chapel Hill. The New IDEAS Study leadership team announced the decision to end new recruitment in March 2024, after considering the feasibility of the study against new structural barriers presented by CMS' retirement of the National Coverage with Evidence Development (CED) of amyloid PET scans. New IDEAS represents one of the largest datasets of its kind and is an important milestone in Alzheimer's research, prioritizing inclusion of patients who self-identify as Black/African American and Hispanic/Latinx, populations that share the greatest burden of dementia.



The Alzheimer's Association International Conference (AAIC), the largest forum to advance dementia science and clinical practice, is where top researchers from across the globe meet to share discoveries and collaborate.

More than 11,000 members of the dementia research community from over 100 countries convened at **AAIC 2023** in Amsterdam, Netherlands, and online, including more than 7,500 in person. Groundbreaking research presented at AAIC 2023 included findings on the impact of hearing aids on cognitive decline; a correlation between opioid use and death in older adults with dementia; the potential for CRISPR/gene editing technology to improve Alzheimer's treatment options; the relationship between constipation and cognitive aging; and a variety of updates on advancements in diagnosis, treatments and clinical trials.

The Association continued to expand its global reach through a growing portfolio of scientific meetings. The NIA and the Association supported the **6th Annual NIA-AA Symposium on Enabling Precision Medicine for Alzheimer's Disease Through Open Science** as part of AAIC 2023 preconference offerings. Convening over 200 members of the research community, the meeting was a valuable opportunity to learn and share developments in precision medicine principles and open science practices.

AAIC Neuroscience Next showcased the work of neuroscience students, postdoctoral researchers and early career research professionals worldwide in a unique "hybrid hub" model. More than 2,500 registrants from 88 countries gathered online to learn from and support the next generation of researchers.

The **AAIC Satellite Symposium** in Cape Town, South Africa, and online brought together more than 360 researchers to discuss research advances in public health, diagnosis and treatment within Africa. Fifty percent of attendees were based in low- and middle-income countries.

The **Tau2024 Global Conference**, held in partnership by the Alzheimer's Association, CurePSP and The Rainwater Charitable Foundation, convened leading global researchers from academia, industry and government to explore the latest findings in tau research and increase interdisciplinary alignment and collaboration around challenges. Nearly 1,200 researchers gathered in Washington, D.C., and online.

The fourth **Latinos and Alzheimer's Symposium** in San Diego and online brought together more than 500 researchers, clinicians and dementia care professionals who work with Hispanic and Latino/a/e/x populations to examine challenges including underrepresentation in clinical trials, barriers to care and the impact of biomarkers on treatment options.

The **AAIC Advancements: Toward Health Equity in Alzheimer's Disease and Related Dementias (ARD)**

conference, held in San Antonio and online in FY24, works to support vital health equity in Alzheimer's research and drive collaboration across the dementia science field among researchers at all career stages. The meeting attracted more than 1,000 participants from over 60 countries.

The Southeastern Neurodegenerative Disease Conference (SENDCon) in Atlanta convened more than 500 researchers based in the southeastern United States and Puerto Rico to build a network of collaboration around the study of neurodegenerative disorders.

The Association, the American College of Radiology, the American Society of Neuroradiology, the Department of Biostatistics, Brown University School of Public Health and the ALZ-NET Project Team, along with other clinical research experts, continued to collaborate on the **Alzheimer's Network for Treatment and Diagnostics (ALZ-NET)**. Led by the Association, which provided the initial funding, ALZ-NET is designed to collect routine clinical practice data from health care professionals caring for people living with Alzheimer's who are taking an FDA-approved disease-modifying treatment, with a goal of quickly and transparently sharing data and outcomes. At the conclusion of the fiscal year, ALZ-NET had over 200 clinical sites in various stages of the startup process — including 60 fully active sites with over 600 patients enrolled — and is also aligning with international registry efforts across 11 other countries.

ALZ-NET is designed to work collaboratively with affiliated studies, including those conducted by academia, industry, federal agencies and ALZ-NET project teams. In FY24, **ALZ-NET was approved by CMS** as a Coverage with Evidence Development (CED) study and can be used as a pathway to Medicare coverage for anti-amyloid Alzheimer's therapies that have received traditional FDA approval.

ALZ-NET International continued to connect ALZ-NET with real-world data platforms globally, providing opportunities to share resources, exchange ideas and amplify impact. ALZ-NET International partners meet quarterly to share updates and initiatives, including at AAIC. Countries represented at the meetings included Australia, Germany, Iceland, Japan, Netherlands, South Korea, Sweden, Turkey, United Kingdom and the United States.

The Association announced the **Global Real-World Data Platforms Program (ALZ-RWD)** — a funding program to support the advancement of and opportunities for real-world data (RWD) platforms and bridging to ALZ-NET. This peer-reviewed funding program will augment and

accelerate global initiatives aimed at developing, expanding and aligning RWD platforms' infrastructure, data and impact. It was launched in October 2023 and received six full applications for review and adjudication for funding in early FY25.

The **Alzheimer's Association Clinical Meaningfulness Workgroup**, formed in 2022 as part of the Association's efforts to provide resources for clinicians about the benefits and risks of FDA-approved amyloid-targeting therapies for Alzheimer's, published in October 2024 recommendations and suggested language to help health care providers explain newly approved Alzheimer's treatments to patients and caregivers.

"Revised Criteria for Diagnosis and Staging of Alzheimer's Disease" was published June 2024 in *Alzheimer's & Dementia*[®]: *The Journal of the Alzheimer's Association*, with corresponding commentaries published in *Nature Medicine* and *Nature Aging*. The 2024 version built off of the 2011 National Institute on Aging and Alzheimer's Association (NIA-AA) clinical guidance and 2018 NIA-AA research framework. The new criteria aim to improve current diagnosis, including accuracy; provide context for a biological definition that will inform the next generation of clinical trials; and lay a foundation that moves us toward personalized approaches for Alzheimer's treatment that are rooted in biology.

The Association announced an investment of \$10.85 million to the **EQT Life Sciences' LSP Dementia Fund**, an international venture capital fund that invests in companies developing promising, high-impact treatments for Alzheimer's and other neurodegenerative diseases. In another example of how the Association is accelerating innovation in dementia research, the commitment expands its funding into broader and varied areas of drug development to advance and diversify the research pipeline and available treatments for people living with Alzheimer's or another dementia.

The third **Alzheimer's Association Interdisciplinary Summer Research Institute** provided a free, immersive opportunity for early career researchers in psychosocial care and public health to launch a career in dementia science and accelerate breakthroughs. Throughout the five-day program, which featured faculty from the Association, 24 attendees — 36% of whom represented a diverse population — learned from experts through group sessions and individual mentoring.

TrialMatch[®] is the Association's free service offering customized lists of clinical studies based on user-provided information. The TrialMatch database has over 3,000 users per month and includes more than 900 clinical trials, including New IDEAS, LEADS, and international studies and locations. In FY24, TrialMatch had 56,440 unique web views, nearly 40,000 online sessions, 3,170 web-based referrals and over 8,400 calls.

The **Alzheimer's Association Research Roundtable (AARR)** engages scientists from the pharmaceutical, biotechnology, diagnostics, imaging and cognitive testing industries worldwide in a precompetitive platform to discuss key areas in Alzheimer's science, with a mission of advancing the research, development and management of new treatments. The roundtable met twice in FY24. The fall 2023 meeting was titled Application of Revised ATN Classification: Drug Development & Clinical Practice, and the spring 2024 meeting was titled System Readiness and the Patient Care Pathway for Alzheimer's Disease Diagnosis and Treatment. Each was attended by over 150 attendees, including scientific leaders from the AARR membership, academia, the NIH, FDA and other global government agencies.

For the eighth year, the **Alzheimer's Association Business Consortium (AABC)** continued to advance Alzheimer's and dementia research through innovation by small, startup biotechnology, diagnostic and contract research organizations. The AABC works to achieve its goals by focusing on areas of common interest to advance the field as well as the goals of its more than 50 member companies. The AABC hosted its annual in-person meeting during AAIC in Amsterdam, with over 20 member companies represented.

In part due to advocacy of the Association and the separately incorporated Alzheimer's Impact Movement (AIM), CMS **expanded coverage of brain amyloid positron emission tomography (PET) imaging for the diagnosis of Alzheimer's disease**. The new policy will remove unnecessary barriers to this important diagnostic and patient safety tool.

The Association continued to champion new treatments, celebrating the FDA's **traditional approval of lecanemab (Leqembi)**[®] for the treatment of early Alzheimer's disease with confirmation of elevated beta-amyloid. This was the first traditional approval of an Alzheimer's treatment that changes the underlying course of the disease.

The **Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART)** is a diverse global network of over 13,000 scientists,

clinicians and dementia professionals in more than 120 countries. ISTAART professional interest areas (PIAs) — subgroups of researchers who share common scientific interests — engaged with their members through 122 webinars and networking sessions, which received over 6,700 live views; published 19 journal articles; and contributed 15 featured research sessions to AAIC 2023. In addition, the FY24 ISTAART Ambassador cohort included 31 ambassadors from 14 countries who delivered the "Introduction to ISTAART" presentation to over 1,700 scientists, clinicians and dementia professionals worldwide.

The **Alzheimer's & Dementia journal family** comprises four open access journals: *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, our flagship journal; *Alzheimer's & Dementia: Diagnosis, Assessment and Disease Monitoring (DADM)*; *Alzheimer's & Dementia: Translational Research & Clinical Interventions (TRCI)*; and the newest addition, *Alzheimer's & Dementia: Behavior and Socioeconomics of Aging*. (The latter journal will publish its first issue in winter/spring 2025.) The A&D family of journals aims to bridge knowledge gaps across a wide range of bench-to-bedside investigations in Alzheimer's, dementia and related topics. The impact factor, which is a measure of how frequently publications in the journal are referenced by other papers, are: A&D (13), DADM (4) and TRCI (4.9). Higher impact factors indicate a journal is more frequently cited and included in other research. Our flagship journal continues to be the top-ranked disease-specific journal in clinical neurology.

Funded by the Association, **GAIN** is the first online platform to provide free, instant access to data normally restricted to a handful of Alzheimer's researchers, uniting a diverse and geographically distributed network of partners to foster discovery, collaboration and sharing. With more than 36,000 unique data attributes linking together over 70 research studies with over 710,000 participants, GAIN serves as a one-of-a-kind resource for the global Alzheimer's and dementia community. In FY24, data from the IDEAS (Imaging Dementia—Evidence for Amyloid Scanning) Study were made available on GAIN.

Association President and CEO Joanne Pike, DrPH, was **elected vice chair of the World Dementia Council**. In this leadership role, Pike helps advance the organization's global efforts to improve the lives of people affected by dementia, which include supporting Alzheimer's and dementia research and securing equitable access to treatments.

Increasing Concern and Awareness

The 2024 edition of [Alzheimer's Disease Facts and Figures](#) — the Association's annual in-depth look at the latest national and state-by-state statistics on Alzheimer's disease prevalence, mortality, caregiving, dementia care workforce and costs of care — documented that an estimated [6.9 million people age 65 and older in the United States are living with Alzheimer's dementia](#) and that the cost of care for these individuals is projected to reach \$360 billion, a \$15 billion increase from the previous year. The accompanying special report, [Mapping a Better Future for Dementia Care Navigation](#), provided a comprehensive look into dementia care navigation by surveying dementia caregivers and health care workers on their experiences, challenges, awareness and perceptions of care navigation in dementia care.

The Association's website, [alz.org](#), continued to serve as a valuable resource on Alzheimer's care, support and research, providing services to constituents nearly 19 million times. The Association also delivered critical Alzheimer's information to the public through 5.5 billion total media impressions in traditional and nontraditional forms, including blogs, social media, and paid and earned placements nationally and locally.

Social media continued to be a significant driver in conversation about the disease and the Association's brand, helping to break down stigma through two-way storytelling. The Association's combined social media following on [Facebook](#), [Instagram](#), [TikTok](#), [YouTube](#) and [X](#) increased by 8% from FY23 to a total of nearly 1.5 million users, signaling continued growth in the public's willingness to join in open dialogue about dementia. Engagement with the Association outperformed nonprofit benchmarks, and the Association amplified its reach by developing social toolkits for advocates, volunteers, influencers, and community and corporate partners.

The Association launched [Generation Hope](#), a national brand campaign aimed at demonstrating the value of investing in the Association's mission. Featuring assets in English and Spanish, the campaign highlighted how the Association drives research breakthroughs and promising new treatments, and provides vital care and support.

Each June, the Association recognizes [Alzheimer's & Brain Awareness Month](#) as an opportunity to hold a global conversation about Alzheimer's and all other dementia and the brain. In FY24, the Association encouraged people to [take charge of their brain health](#), offering five suggestions: incorporate healthy habits that may reduce the risk of cognitive decline; learn the early warning signs of Alzheimer's and other dementia; be proactive in addressing

memory and thinking problems; help accelerate disease-related research; and volunteer with the Association.

The Association launched the [10 Healthy Habits for Your Brain](#) public health campaign to reflect growing evidence that shows that modifying certain risk factors and promoting healthy behaviors can reduce the risk of cognitive decline and dementia. The campaign urged people to take charge of their brain health because it's never too early or too late to start.





Amy Grant

Six-time Grammy Award-winning artist [Amy Grant](#) contributed to the Association's digital storytelling series [Music Moments](#), which highlights the emotional connection between music and the moments in life that we never want to lose to Alzheimer's and all other dementia. Grant performed "Trees We'll Never See" and shared why she chose the song and her personal connection with the cause through her parents, both of whom lived with dementia.

NASCAR driver Ryan Blaney and the Ryan Blaney Family Foundation [donated \\$50,000 to the Association](#) to help advance Alzheimer's and dementia research and enhance care and support for families impacted by the disease. Blaney began his foundation in 2019, and it has raised more than \$750,000 to benefit the Association.

More than 11 million family members and friends serve as unpaid caregivers for people living with Alzheimer's or another dementia. During [National Alzheimer's Disease Awareness Month and National Family Caregivers Month](#) in November, the Association highlighted the unique challenges facing Alzheimer's and dementia caregivers and urged them to take care of their own health.

The Association partnered with the [Society for American Baseball Research \(SABR\)](#) to provide Alzheimer's information and resources to people living with the disease and their caregivers through baseball-centric sessions. In addition to the distribution of Association materials to 7,500 SABR members, the partnership resulted in engagement with one Major League Baseball (MLB) team, with additional initiatives to come. The partnership also helped increase awareness of the Association's **Major League Memories** program, designed to engage the Alzheimer's and dementia community with MLB alumni sharing memorabilia and stories.

Teams across MLB, including the Chicago Cubs, Milwaukee Brewers, Oakland Athletics, Philadelphia Phillies, San Diego Padres, San Francisco Giants, Seattle Mariners and St. Louis Cardinals, and the National Hockey League, including the New York Islanders and Tampa Bay Lightning, took part in **Alzheimer's Association Awareness Games**. The games, which saw 300,000 fans attend, featured donated tickets and the opportunity to learn about Association efforts to end the disease.

For the 15th year in a row, the Association placed **among the top large nonprofits** in the annual *NonProfit Times* list of the Best Nonprofits to Work For. The annual survey recognizes and honors employers in the nonprofit sector that have excelled in creating quality workplaces, with an emphasis on employee development, recognition measures and culture.

Strengthening Diversity, Equity and Inclusion

Engaging diverse perspectives is critical to achieving health equity — meaning that all communities have a fair and just opportunity for early diagnosis of Alzheimer’s or another dementia and access to risk reduction, quality care and treatments. The Association continued making strides in FY24 to expand its reach and respond with resources to address the disproportionate impact of Alzheimer’s and all other dementia on underrepresented communities.

In partnership with the Ad Council and creative agency Lopez Negrete Communications, the Association launched new public service announcements through the [“Some Things Come with Age”](#) campaign in an effort to increase early detection of Alzheimer’s and other dementia within Hispanic communities. Developed in English and Spanish, the campaign celebrates the positive aspects of aging while raising awareness of the early signs and symptoms of the disease. The campaign web page has received over 2.4 million visits, with users making more than 508,000 internal clicks to engage and download resources.

Through its [Healthy Brain Initiative \(HBI\)](#) in partnership with the Centers for Disease Control and Prevention (CDC) and Emory University, the Association launched a free, interactive public health curriculum on [health equity and dementia](#). Designed for public health professionals, students and educators, the course is a resource to deepen their knowledge of the interactions of health equity and dementia. In FY24, 733 people enrolled in the training.



To help tribal organizations prepare communities for the growing threat of Alzheimer’s and all other dementia, the Association and the CDC jointly write and facilitate the implementation of [The Healthy Brain Initiative Road](#)

[Map for American Indian and Alaska Native Peoples.](#)

Development of the [new guidebook](#) kicked off in FY24 with support from over 200 community members and experts. It will build upon momentum generated by the first edition in providing tribal leaders with strategies to help shape the public health response to dementia in American Indian and Alaska Native communities.

The Association developed and strengthened partnerships with trusted national and local organizations in FY24. A new partnership with the [Open and Affirming Coalition \(ONA\)](#) of the United Church of Christ aims to raise awareness of Alzheimer’s and all other dementia among LGBTQ+ communities across the country in collaboration with leaders of faith.

The Association announced a two-year partnership with [Alpha Phi Alpha Fraternity, Inc.](#) — the first intercollegiate Greek-letter fraternity established for African American men — to promote brain health and support those affected by Alzheimer’s and other dementia through awareness and education.

A new partnership with the [United Supreme Council of the Ancient and Accepted Scottish Rite of Freemasonry](#) will connect its more than 10,000 members with the Association for education, engagement and volunteer opportunities. The Association also established a partnership between [Sigma Gamma Rho Sorority, Inc.](#) — an international, historically Black sorority with more than 500 chapters — to raise concern and awareness of Alzheimer’s and provide care and support for those impacted by dementia.

In June, the Association brought together members from several national diversity, equity and inclusion partner organizations and trained nearly 200 new **Health Equity Awareness Champions**. These volunteers will deliver presentations to raise awareness of the disease and reach more individuals and families in underrepresented and underserved communities.

The Association and Gdavis Productions and Films, LLC, brought **“Unforgettable,”** a dynamic and emotional stage play that showcases the effects of caring for a loved one living with Alzheimer’s in an easy-to-understand and relatable way, to new audiences in FY24. Eighty-seven percent of respondents to post-show surveys agreed or strongly agreed that the play provided insight into the importance of culturally tailored education and representation. By engaging 150 national and local partners, the play has also enabled the Association to extend its reach into underserved communities.

The Association strengthened the impact of these partnerships through the creation of **ALZ Health Equity Coalitions** — grassroots coalitions tasked with building on the momentum created by “Unforgettable” in local communities. These coalitions work with the Association to ensure greater health equity by improving the state of diagnosis and care for underserved communities.

The Association sponsored the third annual **Black Men’s Brain Health Conference**, bringing together leading brain health and dementia researchers and community leaders. The conference, which had over 2,000 in-person and virtual attendees, focused on the development of community-based strategies for engaging more Black men in Alzheimer’s and dementia research. The Association, in collaboration with the Black Men’s Brain Health leadership, selected 10 emerging scholars to receive additional funding and support.



Advancing Public Policy

The Alzheimer's Association and the Alzheimer's Impact Movement (AIM), a separately incorporated advocacy affiliate, work independently and together to the extent allowed by law to continue to advance federal and state policy priorities. In collaboration with dedicated and passionate advocates, the Association and AIM achieved many successes in FY24 on the national, state and local levels.



Bipartisan congressional leaders announced a [\\$100 million increase for Alzheimer's and dementia research funding](#) at the National Institutes of Health. The efforts of the Association, AIM and volunteers nationwide were instrumental in achieving this funding increase. The bill included \$34 million to fund and continue to implement the [Building Our Largest Dementia \(BOLD\) Infrastructure for Alzheimer's Act](#). Congress reintroduced the BOLD Act in FY24 to strengthen the dementia public health infrastructure in communities across the country.

The Association and AIM worked with congressional champions on the introduction of the [Accelerating Access to Dementia & Alzheimer's Provider Training \(AADAPT\) Act](#) into Congress. This bipartisan legislation is aimed at empowering primary care providers to better understand and diagnose Alzheimer's and all other dementia while emphasizing high-quality, person-centered care in community-based settings.

Association and AIM efforts helped lead to the House Energy and Commerce Committee unanimously passing [four important bipartisan bills](#): the NAPA Reauthorization Act, the Alzheimer's Accountability and Investment Act, the BOLD Infrastructure for Alzheimer's Reauthorization Act and the Lifespan Respite Care Reauthorization Act. The Association and AIM urged swift action by Congress to pass these critical bills, which will grow momentum in the fight against Alzheimer's and all other dementia.

The Centers for Medicare & Medicaid Services (CMS) enabled [access to Food and Drug Administration \(FDA\) traditionally approved Alzheimer's treatments](#). These medications were previously only available to people enrolled in a registry. The Association and AIM partnered with experts and people living with Alzheimer's and their families to urge CMS to change its policy.

Joanne Pike, DrPH, Alzheimer's Association president and CEO and AIM CEO, [testified during a House Energy & Commerce Health Subcommittee hearing](#) to encourage support for important bipartisan Alzheimer's policy priorities. Pike called for swift enactment of legislation that would enable further strides in understanding, treating and preventing Alzheimer's and all other dementia. Association and AIM advocates attended the hearing to show their support for these vital Alzheimer's policies.

More than 1,000 advocates gathered from all 50 states for the [2024 Alzheimer's Impact Movement \(AIM\) Advocacy Forum](#), the nation's premier Alzheimer's disease advocacy event. On [Hill Day](#), advocates shared their stories with elected officials and implored them to advance policies that will help people living with dementia and their caregivers. The advocates met with more than 500 congressional offices, over 80 of which were with a member personally. Meetings were held with all 100 Senate offices and 417 House offices.

At the [National Alzheimer's Dinner](#) during the AIM Advocacy Forum, emceed by actor David Hyde Pierce, advocates celebrated public policy victories, and leaders

were honored for their roles in making Alzheimer's a national priority. Sen. Debbie Stabenow (D-Mich.) received the [Alzheimer's Association Lifetime Leadership Award](#) for introducing or cosponsoring many pieces of Alzheimer's legislation.



Between January and June 2024, each state held a State Advocacy Day event at their capitol building, with events usually comprising one day of targeted advocacy but sometimes spanning several days to a week. Across the country, **more than 2,000 individuals participated in these events**, which are an opportunity to increase the Association and AIM's presence at the state level while building relationships with policymakers.

Alzheimer's advocates secured a **record-breaking \$247.9 million in dementia-specific funding** from state governments, bringing the effective total (when biennial budgets annualized) for 2023 to \$227.9 million — a 26.75% increase in total funding compared to 2022. Of the \$247.9 million, approximately \$40.7 million is for research. Thirty-nine states and the District of Columbia appropriated state funds for Alzheimer's in 2023.

Biomarkers are measurable biological changes that can show if a disease is present or if a person is at risk. By ensuring access to necessary biomarker testing, states can reduce the time it takes to receive a dementia diagnosis and enable access to disease-modifying treatments and care planning. In FY24, the Association joined with a national coalition of patient advocates **committed to ensuring insurance coverage for comprehensive biomarker testing**. Six states enacted legislation to help ensure access to biomarker testing.

Increasing Revenue

Constituents, corporations and organizations helped fuel the Association's vision of a world without Alzheimer's and all other dementia through their generous support. Donor and partner contributions for the Association totaled nearly \$398 million in FY24.

Strategic direct marketing efforts using print and digital campaigns raised **\$77.2 million and engaged more than 600,000 donors**. More than \$3.9 million was raised on Facebook and Instagram through birthday and evergreen fundraisers, and signature event fundraisers contributed an additional \$4 million. Alternative giving opportunities through Facebook Challenges raised nearly \$265,000.

Walk to End Alzheimer's raised a record-breaking \$100 million for the season — a 10% increase over the prior season. More than 350,000 participants came together for the world's largest event to raise awareness and funds for Alzheimer's care, support and research. In addition, 11 new companies and organizations joined as National Teams, growing the total to 67; these teams raised more than \$14.4 million. Walk retained its second-place standing in the Peer-to-Peer Forum's Top 30 rankings for all fundraising runs, walks and cycling events nationwide.

Eisai joined as a new Walk to End Alzheimer's National Sponsor in FY24. The pharmaceutical company had a presence at Walk in 25 communities across the country to interact with the people they serve.

In another record-breaking season, **The Longest Day®** raised \$13 million, including \$3 million from 17 Global Teams. Thousands of participants from around the world used their creativity and passion to raise funds and awareness for the Association through activities such as pickleball, golf, running and hiking. The American Contract Bridge League (ACBL) participated in The Longest Day for its 13th year, raising more than \$1.2 million in FY24 and \$11 million total.



Ride to End ALZ®, the Association's signature cycling event that raises funds for Alzheimer's research, garnered over \$4.7 million — an 11% increase from FY23. Nearly 5,000 individuals participated in six in-person rides and three virtual opportunities to ride in a location of the participants' choice.

Founded in 2012 by Michaela "Mikey" Hoag, the Alzheimer's Association **Part the Cloud** innovative grant funding program is a movement to accelerate scientific progress in Alzheimer's research. Part the Cloud has raised over \$83 million to fuel 71 research projects that have gone on to receive more than \$1.4 billion in follow-on funding. In FY24, the Part the Cloud Gala, held in Woodside, California, raised over \$17 million to advance high-risk, high-reward research projects aimed at potential new treatments and devices for Alzheimer's and all other dementia.

The **Jerome H. Stone Philanthropy Award for Alzheimer's Research** recognizes the world's top philanthropists for advancing dementia science through their generous and transformative financial commitments. The Association presented **2024 awards** to **John and Crystal Beuerlein** and the financial services firm **Edward Jones**, who have advanced a variety of Alzheimer's research projects in partnership with the Association, including the Dominantly Inherited Alzheimer Network Trials Unit. John Beuerlein also co-chaired Step Up the Pace, a special philanthropic initiative that raised nearly \$110 million in four years to fund Association investments in dementia science.

For the eighth consecutive year, Edward Jones **continued its strategic alliance with the Association**, contributing over \$5.8 million through corporate donations, Walk to End Alzheimer's teams and associate-driven efforts. As the National Presenting Sponsor of Walk to End Alzheimer's, Edward Jones mobilized 12,700 participants across 3,000 teams, raising more than \$3.6 million. Since 2016, Edward Jones and its associates have raised more than \$45 million for the fight to end Alzheimer's, with a pledge to reach \$50 million by 2025.

The [Zenith Society](#) — comprising philanthropists who make a commitment of \$1 million or more to the Association — sets the bar for philanthropic leadership, engagement and impact. The Society welcomed four new members, increasing its total to 105. Zenith-level commitments received included gifts to support research from the Ray and Dagmar Dolby Family Fund; GHR Foundation; Mikey and Jay Hoag; Dick Kipper; the William and Sheila Konar Family Foundation; the Leeolou Family Foundation; National Active and Retired Federal Employees (NARFE); the Samuels Family Foundation; the WoodNext Foundation (a component fund administered by Greater Houston Community Foundation); and The Anne and Henry Zarrow Foundation. The Konar Family Foundation's gift established the William and Sheila Konar Health Services Research Initiative. Zenith Society members generated a total of \$68 million to advance the Association's mission through personal gifts, special events, direct marketing challenges, Walk to End Alzheimer's and more.

The [Aspire Society](#) recognizes individuals and foundations who give \$10,000 or more per year through outright gifts, galas, Walk to End Alzheimer's and other avenues to advance Alzheimer's care, support and research. In FY24, the Association was honored to acknowledge 1,500 Aspire Society members.

The [Founders Society](#) honors the extraordinary people who make future gift commitments to the Association through their estate plans. The Association welcomed 219 new Founders Society members, bringing membership to more than 2,800. The Association received over \$78 million as a beneficiary of wills, trusts, charitable gift annuities and other planned gift arrangements.

The [Alois Society](#), which includes donors who make an annual gift of \$1,000 to \$9,999, raised \$19.9 million to help fuel and guide the Association's efforts.

Revenue from **generous corporate contributors** totaled \$21.1 million and earned millions of impressions to increase concern and awareness of Alzheimer's and all other dementia. A complete list of corporate supporters at the \$50,000 level and above is available later in this report.

With the support of its dedicated customers, [Marshalls](#) — one of the nation's leading off-price family retailers — raised more than \$1.9 million for the Association through an in-store fundraising campaign. Since 2013, Marshalls customers have contributed nearly \$20 million to help advance the Association's mission.

[BJ's Restaurants, Inc.](#), was a Proud Supporter of The Longest Day for a sixth consecutive year. Throughout June 2024, BJ's Restaurant & Brewhouse guests who dined in or ordered takeout were invited to donate to the Association. Nearly \$150,000 was raised through guest donations and a company match on The Longest Day.

[CNO Financial Group and Bankers Life](#) held the 22nd annual Forget Me Not Days® fundraiser supporting The Longest Day as a Global Team. A contribution of more than \$400,000 was made through corporate, public and associate donations. As a Walk to End Alzheimer's National Team, CNO and Bankers Life participated as sponsors in both Chicago and Indianapolis. Their total efforts have raised more than \$7.8 million since 2003.

To help people age confidently at home, [Procter & Gamble](#) continued to provide resources to maintain independence and promote home safety through a \$200,000 corporate gift and employee participation as a Walk to End Alzheimer's National Team. Since 2017, P&G has contributed more than \$1.65 million to the Association.

The Alzheimer's Association and Gdavis Productions and Films LLC brought ["Unforgettable,"](#) a powerful stage play that showcases the effects of caring for a loved one living with Alzheimer's, to cities across the nation for a second year in a row. Sponsors **Molina Healthcare, Lilly and Edward Jones** contributed \$230,000 to the Association.

Continued support from the pharmaceutical, biotech and life science industries **helped advance critical scientific initiatives**, including AAIC 2023, the Alzheimer's Association Research Roundtable (AARR), the Alzheimer's Disease Neuroimaging Initiative Private Partner Scientific Board (ADNI-PPSB), Project ECHO Superhub, AAIC Advancement Conferences, the Dementia Care Navigation Roundtable and the Alzheimer's Association Innovation Roundtable (AAIR).

Built on the legacy of the Rita Hayworth Gala, the [Alzheimer's Association Imagine Benefit](#) raised nearly \$800,000. Founded by Princess Yasmin Aga Khan in honor of her mother, actress Rita Hayworth, the event was held at the iconic Jazz at Lincoln Center in New York City. Highlights included performances from Darren Criss, Colton Ryan and Ballet Hispanico.

Hallmark stars Ashley Williams and Nikki DeLoach hosted the sixth annual [Dance Party to End ALZ](#) in Nashville. The event, which was founded by Kimberly Williams-Paisley, raised more than \$300,000 for the Association's research grant program.



Treasurer's Report

The financial health of the Alzheimer's Association was strong in FY24, with the organization's Consolidated Statement of Financial Position reflecting total assets of more than \$526 million as of the fiscal year ended June 30, 2024. Total revenues were more than \$465 million, with over \$398 million from donor contributions.

Expenses were well managed. Of the total consolidated expenses of \$476 million, the Association expended \$366 million on programmatic activities. The Association continues to meet and exceed minimum standards of 65% program expenses set by the BBB Wise Giving Alliance, devoting 77% of expenses to programmatic activities.

Continuing to make significant progress in the fight to end Alzheimer's in FY24, the Association made its largest-ever total annual research investment, granting \$109 million in total annual research spending, including more than \$76 million in grants for new scientific investigations. As the world's leading nonprofit funder of Alzheimer's and dementia research, the Association is currently investing over \$430 million in more than 1,110 active best-of-field projects in 56 countries.

Among other achievements, we provided care and support more than 10 million times through channels including alz.org, our 24/7 Helpline (800.272.3900), support groups and education programs. We strengthened our commitment to overcoming barriers that prevent diverse communities from accessing Alzheimer's education, care and support, and made significant progress in expanding resources to address the disproportionate impact of Alzheimer's and all other dementia on underrepresented groups. And due to the relentless efforts of the Association and the Alzheimer's Impact Movement, a separately incorporated advocacy affiliate, Congress approved a \$100 million increase in federal Alzheimer's and dementia funding, bringing the total current federal research investment to as much as \$3.8 billion.

We are grateful for the trust our donors place in us and for their support and commitment to helping us achieve our vision: a world without Alzheimer's and all other dementia.

Dean Brenner

FY24 Treasurer, Board of Directors

Alzheimer's Disease and Related Disorders Association, Inc.

Consolidated Statement of Financial Position

Year ended June 30, 2024

(In thousands)

ASSETS	2024	2023
Cash and cash equivalents	\$46,171	\$33,805
Pledges receivable, net	58,297	70,014
Other receivables, net	10,009	9,127
Inventories of education materials, at cost	1,137	1,140
Investments	304,945	293,712
Prepaid expenses	9,059	6,890
Assets held in trust	20	46
Fixed assets, net	19,666	22,544
Right-of-use operating assets	39,643	40,680
Beneficial interest in split-interest agreements	6,315	6,432
Beneficial interest in perpetual trusts	30,725	28,567
Other assets	747	770
TOTAL ASSETS	\$526,734	\$513,727
LIABILITIES AND NET ASSETS		
LIABILITIES		
Accounts payable	\$10,351	\$9,222
Grants payable, net	117,425	119,715
Deferred compensation payable	845	822
Accrued expenses and other liabilities	32,782	29,270
Self-insurance reserve	1,278	1,469
Gift annuity obligations	5,707	5,897
Contract liability	5,412	5,329
Operating lease obligations	46,440	48,247
TOTAL LIABILITIES	220,240	219,971
NET ASSETS		
Without donor restrictions	147,553	145,884
With donor restrictions	158,941	147,872
TOTAL NET ASSETS	306,494	293,756
TOTAL LIABILITIES AND NET ASSETS	\$526,734	\$513,727

These financial statements have been prepared by management in conformity with generally accepted accounting principles and include all adjustments which, in the opinion of management, are necessary to reflect a fair presentation. This presentation represents a summarization from audited financial statements.

Alzheimer's Disease and Related Disorders Association, Inc.

Consolidated Statement of Activities

Year ended June 30, 2024

(In thousands)

	Without Donor Restrictions	With Donor Restrictions	Total
REVENUES, GAINS AND OTHER SUPPORT			
Contributions:			
Cash and other financial assets	\$342,277	\$89,133	\$431,410
Non-financial assets	11,370	-	11,370
Conference registration and other	12,309	-	12,309
Dividends and interest, net of investment-related expenses	8,965	1,545	10,510
Net assets released from restrictions	81,257	(81,257)	-
TOTAL REVENUES, GAINS AND OTHER SUPPORT	456,178	9,421	465,599
EXPENSES			
PROGRAM SERVICES			
Care, support and risk reduction	105,676	-	105,676
Research	105,802	-	105,802
Concern and awareness	112,207	-	112,207
Diversity, equity and inclusion	9,670	-	9,670
Public policy	28,965	-	28,965
Mission engagement	4,140	-	4,140
TOTAL PROGRAM SERVICES	366,460	-	366,460
SUPPORTING SERVICES			
Fundraising	85,056	-	85,056
Management and general	24,438	-	24,438
TOTAL SUPPORTING SERVICES	109,494	-	109,494
TOTAL EXPENSES	475,954	-	475,954
(DEFICIENCY) EXCESS FROM OPERATIONS	(19,776)	9,421	(10,355)
OTHER CHANGES IN NET ASSETS			
Net realized and unrealized gains (losses) in value of investments	21,691	(93)	21,598
Change in value of split-interest agreements	(246)	(416)	(662)
Change in value of perpetual trusts	-	2,157	2,157
TOTAL OTHER CHANGES IN NET ASSETS	21,445	1,648	23,093
CHANGE IN NET ASSETS	1,669	11,069	12,738
NET ASSETS AT BEGINNING OF YEAR	145,884	147,872	293,756
NET ASSETS AT END OF YEAR	\$147,553	\$158,941	\$306,494

These financial statements have been prepared by management in conformity with generally accepted accounting principles and include all adjustments which, in the opinion of management, are necessary to reflect a fair presentation. This presentation represents a summarization from audited financial statements.

Corporate Supporters

Annually, the generosity of corporate supporters and their employees helps the Alzheimer's Association to advance vital research and provide educational programming, care and support. We greatly appreciate their continuing contributions to our mission.

\$1,000,000+

Edward Jones
Eisai
Marshalls/TJX Foundation

\$500,000 – \$999,999

Biogen
Eli Lilly & Company
Genentech/Roche

\$250,000 – \$499,999

Bank of America
CARS
CNO Financial Group/Bankers Life
Goldman Sachs
Lundbeck
Molina Healthcare
Novo Nordisk
Rolex Watch USA

\$100,000 – \$249,999

Abbott Laboratories
AbbVie
Acumen Pharmaceuticals
BJ's Restaurant & Brewhouse
Bristol-Myers Squibb
C2N Diagnostics LLC
Costco
Estes Express Lines
Genworth
Google
H-E-B
Janssen/Johnson & Johnson
Jersey Mike's
Lantheus
Liberty Mutual
Microsoft
MPG Corporation
NRG Energy Inc.
OnStar
Otsuka Pharmaceuticals
Procter & Gamble

Prothena Biosciences
Qintel LLC
Raymond James
Riversource Life Insurance Company
Stryker Johnston Foundation
UnitedHealth Group

\$50,000 – \$99,000

Accenture
Adobe
Alector
Alzheimer's Disease Data Initiative Inc.
Alzheon
Athria Pharma
Ameriprise
Apple
AT&T
BAYADA Home Health
Beckman Coulter
Boeing
Cboe Global Markets
Charter Mechanical Contractors, Inc.
Chevron
Cisco
Cogstate
Dell
Dignity Health
Elevance Health
Enigma Biomedical Group
Enterprise
E.R. Squibb & Sons LLC
Exelon
Farm Bureau Health Plans
Fujirebio Diagnostics
GIE Media
Goodcents
Home Instead
HearingLife
IBM
Illinois Tool Works
Jack Daniel's Distillery
Merck
Merrill Gardens

Methodist Healthcare
Novartis
Renasant Bank
RetireMed
Round Pond Estate
Senior Star
Sentara Healthcare
Sharon Towers
Signant Health
Takeda
TauRx Pharmaceuticals
U.S. Bank Foundation
Vaccinex Inc.
WCG Clinical
Wellington Management
Wells Fargo

Walk to End Alzheimer's National Teams/ The Longest Day Global Teams

Walk to End Alzheimer's National Teams and The Longest Day Global Teams are committed to raising critical funds and awareness for Alzheimer's care, support and research. We recognize these leading fundraising teams and thank them for joining the Alzheimer's Association in our fight to end Alzheimer's and all other dementia.

\$3,000,000+

Edward Jones

\$1,000,000+

American Contract Bridge League
American Senior Housing Association
Brookdale Senior Living
Sigma Kappa

\$500,000 – \$999,999

Alzheimer's/Dementia Rotary Action Group
Life Care Services
Senior Star

\$250,000 – \$499,999

Alpha Delta Kappa
Home Instead
Parrot Heads In Paradise
UnitedHealth Group
Visiting Angels

\$100,000 – \$249,9999

American Academy of Estate Planning Attorneys
Always Best Care Senior Services
Bankers Life
Belmont Villages
Brightview Senior Living
Charter Senior Living
Cisco
Comfort Keepers
Dot Foods
Erickson Senior Living

Frontier Management
Integrated Financial Group
International Council on Active Aging
KPMG
Mah Jongg for Memories
Naples Pickleball Center
National Active and Retired Federal Employees
National Healthcare Corporation
Prager Metis
ProMedica Senior Care
Senior Lifestyle
Senior Living Communities
Sinceris Senior Living
Sunrise Senior Living
The Judy Fund

\$50,000 – \$99,000

agilon health
American House Senior Living
Americare Senior Living
Artis Senior Living
Bank of America
BAYADA Home Health
CarePatrol
Genesis HealthCare
Grant Thornton
Jaybird Senior Living
Life Care Centers of America
LifeSpace Communities
Merrill Gardens
Oasis Senior Advisors
Onelife Fitness
Salesforce

Alzheimer's Association Leadership Teams

Board of Directors

Members of the Alzheimer's Association Board of Directors volunteer to serve multiyear terms. They generously support our efforts with their time, talent and passion.

Chair

Sarah Lorance

Chair Elect

Minoo Javanmardian, Ph.D.

Vice Chair

Karyne Jones

Secretary

Debra Pierson

Treasurer

Bruce Baude

Executive Committee

Joe Arciniega
Dean Brenner
Dozene Guishard, Ed.D.
Geoff Heredia
Bruce Lamb, Ph.D.
Alex Tsao, Ph.D.
Derek van Amerongen, M.D.
George Walz

Directors

Rushern Baker
Gabriel de la Rosa
Wendy Drummond
Chuck Garrett
David Gonzales
Tony Gonzales
Bret Hill
Mikaela Louie
Cynthia Moore-Hardy
Donald Plaus
Elizabeth Shih
Irene Sudac
William Thomas
Nicole Walker
Nancy Westcott

Medical and Scientific Advisory Group

Chair

Bruce T. Lamb, Ph.D.

Vice Chair

Oscar Lopez, M.D.

Members

Karen Bell, M.D.
Lea Grinberg, M.D., Ph.D.
Lee A. Jennings, M.D., MSHS
Malú Tansey, Ph.D.
Christopher van Dyck, M.D.

Alzheimer's Association

Maria C. Carrillo, Ph.D.

Alzheimer's Association
225 N. Michigan Ave., Fl. 17
Chicago, IL 60601

ALZHEIMER'S ASSOCIATION®

Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support.

Our vision is a world without Alzheimer's
and all other dementia®.

800.272.3900 | [alz.org](https://www.alz.org)®

©2024 Alzheimer's Association. All rights reserved. This is an official publication of the Alzheimer's Association but may be distributed by unaffiliated organizations and individuals. Such distribution does not constitute an endorsement of these parties or their activities by the Alzheimer's Association.